You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants
  1. Anne Greenough
  1. Division of Asthma, Allergy and Lung Biology, NICU, King's College Hospital, King's College London, London, UK
  1. Correspondence to : Professor Anne Greenough, Division of Asthma, Allergy and Lung Biology, NICU, King's College Hospital, King's College London, Denmark Hill, London, SE5 9RS, UK; anne.greenough{at}kcl.ac.uk

https://doi.org/10.1136/eb-2013-101437

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791–9.OpenUrlCrossRefPubMedWeb of Science

    Context

    Respiratory syncytial virus (RSV) and lower respiratory tract infections (LRTIs) are associated with chronic respiratory morbidity (CRM) at follow-up. In infants born very prematurely who had bronchopulmonary dysplasia (BPD), RSV LRTIs were associated with greater lung function abnormalities and healthcare utilisation at school age.1 A prospective study2 demonstrated that among very prematurely born infants (<32 weeks of gestational age) regardless of the BPD status and whether hospitalisation was required, RSV LRTIs were associated with increased CRM and lung function abnormalities at follow-up in infancy. Even among infants born between 32 and 35 weeks of gestation, the mean cost of care in …

    View Full Text

    Footnotes

    • Competing interests None.